Sanofi to shoulder cost of proven Dengvaxia-related cases

Patrick Quintos, ABS-CBN News

Posted at Jan 22 2018 03:10 PM

MANILA - French drug maker Sanofi Pasteur will shoulder cost of any incident, be it death or other cases, "causally-related" to its controversial vaccine, Dengvaxia.

A worker shows used anti-dengue vaccine Dengvaxia inside a vaccine storage room in Sta. Cruz, Metro Manila. Reuters CHICAGO/LONDON - When French drugmake

In a Senate hearing Monday, Sanofi's Thomas Triomphe said the company is willing to shoulder the costs of the cases provided they are scientifically proven.

"Should there be any case relative to vaccination, be (it) death or any other case, we'll shoulder the cost if there is causality but has been demonstrated to scientific evidence," he said.

Triomph's statement came after a parent who attended the hearing shared how his child, who completed the Dengvaxia vaccine doses, died last December 2017, allegedly due to dengue.

"Nagwa-wild siya sa ospital. Hindi siya makakilala ng tao," Mr. Culite, a father from Imus, Cavite told senators.

He added that his child also experienced stomach ache and rashes.

He said the hospital where his child died initially claimed that the cause of death was appendicitis but later on told their city health office that the actual cause of death was dengue.

But Senator Richard Gordon, Blue Ribbon Committee chair, said a scientist is needed to confirm if the child of Mr. Culite indeed died of dengue.

Sanofi earlier said in a "supplementary" clarification that individuals who received Dengvaxia with no prior history of dengue face "increased risk of hospitalization for dengue and severe dengue."

This controversy prompted the Department of Health to suspend the vaccine program. Sanofi earlier agreed to refund the P1.4 million cost of unused Dengvaxia doses after this.